Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB/Hib™, Concomitantly With OPV in Healthy Infants

Inclusion Criteria: At Screening: * 0 to 3 day old infants * Born at full term of pregnancy (≥ 37 weeks) with a birth weight ≥ 2.5 kg * Apgar score ≥ 7 at three minutes after birth * Informed consent form signed by one parent or legal representative if appropriate (independent witness mandatory if parent is illiterate) At Inclusion: * Six weeks of age * Received a dose of Hepatitis B (HB) in the first three days of life * Able to attend all scheduled visits and to comply with all trial procedures. Exclusion Criteria: At Screening: * Illness at a stage that could interfere with trial conduct or completion * Any vaccination before HB vaccination (except bacille Calmette-Guérin \[BCG\] given at birth) * Vaccination planned in the 4 to 6 weeks following the first trial vaccination (except BCG if not given at birth) * Acute illness on the day of screening. At Screening and at Inclusion: * Blood or blood-derived products received since birth * Planned participation in another clinical trial during the present trial period * Mother known as seropositive to Human immunodeficiency virus (HIV) or Hepatitis C, or as carrying the HB surface antigen (HBsAg) * Known thrombocytopenia or bleeding disorder contraindicating intramuscular vaccination * Known hypersensitivity to any component of any vaccine to be used in the trial (including neomycin and polymixin B) At Inclusion: * Non-trial vaccine administered since birth, except Bacille Calmette-Guérin (BCG) * Participation in another clinical trial before the first trial vaccination * Congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term systemic corticosteroid therapy * Systemic hypersensitivity to any of the vaccine components or history of a life threatening reaction to the trial vaccine or a vaccine containing the same substances * Chronic illness at a stage that could interfere with trial conduct or completion * Vaccination other than with the study vaccines planned in the 12 weeks following inclusion * Documented history of pertussis, tetanus, diphtheria, polio, H. influenza type b, or HB infection (confirmed clinically, serologically, or microbiologically) * History of seizures * Febrile (rectal temperature ≥ 38.0°C) or acute illness on the day of inclusion.